Ahmed Kotb/X
Jul 26, 2026, 13:32
Ahmed Kotb: A Practical Guide to Von Willebrand Disease
Ahmed Kotb, Hematologist and Bone Marrow Transplant Physician at King Faisal Specialist Hospital International Holding Company (KFSHI), shared a post on X:
”Von Willebrand Disease (VWD)
Type 1: Partial decrease in von Willebrand factor (VWF) – usually responds to desmopressin (DDAVP).
Type 2: Qualitative defect in VWF.
- Type 2A: Decreased high-molecular-weight (HMW) multimers.
- Type 2B: Increased binding to platelet glycoprotein Ib (GPIb), resulting in thrombocytopenia; avoid DDAVP.
- Type 2M: Decreased platelet adhesion.
- Type 2N: Decreased binding to factor VIII (FVIII).
Type 3: Complete absence of VWF, causing severe disease; treat with VWF/FVIII concentrate.
Laboratory findings: Decreased VWF antigen, decreased VWF activity, and factor VIII may be decreased.”
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice